Genelabs taps Taiwan expertise for hepatitis C
This article was originally published in Scrip
Executive Summary
Genelabs Technologies has forged a basic research alliance with two Taiwanese partners that it hopes will speed up the development of novel candidate compounds for the treatment of hepatitis C.